Skip to content
2000
Volume 9, Issue 2
  • ISSN: 1574-891X
  • E-ISSN: 2212-4071

Abstract

The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.

Loading

Article metrics loading...

/content/journals/pri/10.2174/1574891X10666150326114221
2014-08-01
2025-09-15
Loading full text...

Full text loading...

/content/journals/pri/10.2174/1574891X10666150326114221
Loading

  • Article Type:
    Research Article
Keyword(s): AVI-6002; AVI-7537; AVI-7539; BCX4430; brincidofovir; Ebola; favipiravir; TKM-100802
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test